TY - JOUR AU - Lee, Nancy AU - Woodrum, Chelsey L. AU - Nobil, Alison M. AU - Rauktys, Aubrey E. AU - Messina, Michael P. AU - Dabora, Sandra L. PY - 2009 DA - 2009/04/15 TI - Rapamycin weekly maintenance dosing and the potential efficacy of combination sorafenib plus rapamycin but not atorvastatin or doxycycline in tuberous sclerosis preclinical models JO - BMC Pharmacology SP - 8 VL - 9 IS - 1 AB - Tuberous sclerosis complex (TSC) is an autosomal dominant tumor suppressor syndrome, characterized by hamartomatous growths in the brain, skin, kidneys, lungs, and heart, which lead to significant morbidity. TSC is caused by mutations in the TSC1 or TSC2 genes, whose products, hamartin and tuberin, form a tumor suppressor complex that regulates the PI3K/Akt/mTOR pathway. Early clinical trials show that TSC-related kidney tumors (angiomyolipomas) regress when treated with the mammalian target of rapamycin (mTOR) inhibitor, rapamycin (also known as sirolimus). Although side effects are tolerable, responses are incomplete, and tumor regrowth is common when rapamycin is stopped. Strategies for future clinical trials may include the investigation of longer treatment duration and combination therapy of other effective drug classes. SN - 1471-2210 UR - https://doi.org/10.1186/1471-2210-9-8 DO - 10.1186/1471-2210-9-8 ID - Lee2009 ER -